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Nonculture-based tests are gaining popularity in the diagnosis of invasive fungal disease (IFD), but PCR is excluded from dis-
ease-defining criteria because of limited standardization and a lack of commercial assays. Commercial PCR assays may have a
standardized methodology while providing quality assurance. The detection of PCR products by a surface-enhanced Raman
scattering (SERS) assay potentially provides superior analytical sensitivity andmultiplexing capacity compared to that of real-
time PCR. Using this approach, the RenDx Fungiplex assay was developed to detect Candida and Aspergillus. Analytical and clin-
ical evaluations of the assay were undertaken using extractionmethods according to European Aspergillus PCR Initiative
(EAPCRI) recommendations. A total of 195 previously extracted samples (133 plasma, 49 serum, and 13 whole blood) from 112
patients (29 with proven/probable IFD) were tested. The 95% limit of detection of Candida and Aspergilluswas 200 copies per
reaction, with an overall reproducibility of 92.1% for detecting 20 input copies per PCR, and 89.8% for the nucleic acid extrac-
tion–PCR-SERS process for detecting fungal burdens of<20 genome equivalents per sample. A clinical evaluation showed that
assay positivity significantly correlated with IFD (P< 0.0001). The sensitivity of the assay was 82.8% and was similar for both
Candida (80.0%) and Aspergillus (85.7%). The specificity was 87.5% and was increased (97.5%) by using a multiple (>2 samples)
PCR-positive threshold. In summary, the RenDx Fungiplex assay is a PCR-SERS assay for diagnosing IFD and demonstrates
promising clinical performance on a variety of samples. This was a retrospective clinical evaluation, and performance is likely to
be enhanced through a prospective analysis of clinical validity and by determining clinical utility.
The use of nonculture-based tests can enhance the diagnosis ofinvasive fungal disease (IFD) (1, 2). While antigen detection
(galactomannan enzyme immunoassay [EIA] and [1,3]--D-glu-
can) is widely used, molecular-based detection (PCR) has been
excluded from the revised European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infectious Dis-
eases Mycoses Study Group (EORTC/MSG) disease-defining cri-
teria; this is a consequence of limited standardization and a pau-
city of commercially manufactured assays (3).
Since the publication of the disease-defining criteria, there
have been several advances to standardize molecular diagnostics.
The minimum information required for the publication of quan-
titative PCR experiments (MIQE) guidelines have been proposed
in order to provide a standardized generic approach when devel-
oping and reporting real-time PCR assays (4). Specific to mycol-
ogy, the EuropeanAspergillusPCR initiative (EAPCRI) has offered
recommendations to provide optimal methodology when testing
whole-blood and serum samples by Aspergillus PCR (5, 6). An
international standard has been developed, providing reference
material for assay comparison and validation (7).
Commercial assays have become available for diagnosing inva-
sive aspergillosis (IA) and invasive candidiasis (IC), providing
standardized methodology and quality-controlled development
in line with commercially available antigen-based tests (8–10).
Most commercial PCR tests utilize real-time technology, provid-
ing rapid results for an individual target or a limited number of
targets plus an internal control in a single reaction.Multiplexing is
restricted by the limited number of fluorescent channels available
on the PCR platform. Consequently, they are often inadequate for
syndromic approaches, for which performing multiple PCRs per
sample is neither cost- nor time-efficient. When real-time tech-
nology has been applied, for example, in the investigation of sepsis
using the Roche SeptiFast assay, cases of IFD have been limited,
providing only anecdotal information regarding performance
(11, 12).
Recently, a novel approach to genotyping human papilloma-
virus infection utilized surface-enhanced Raman scattering
(SERS) (13). SERS uses sensitive spectroscopic detection to gen-
erate analyte-specific fingerprint spectra and is particularly suited
to the simultaneous detection of multiple targets (14).
To provide a standardized diagnostic approach, a new SERS
spectroscopy platform, RenDx (Renishaw Diagnostics Limited,
Glasgow, United Kingdom), has been developed for detecting nu-
cleic acid targets, including semiautomated postamplification
processing and multiplex detection using Raman spectroscopy,
and it is capable of detecting up to 10 targets per reaction. Using
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purpose-designed assays, or bymodifying existing PCR protocols,
SERS detection can differentiate between multiple etiological tar-
gets by detecting the presence of oligonucleotides specific for each
pathogen. The essential components for a screening assay target-
ing a low-incidence disease are high sensitivity and concordant
negative predictive value to exclude disease. SERS multiplexing
capacity and analytical sensitivity have the potential to exceed flu-
orescent-based technologies, making it ideal for such an applica-
tion (14).
Using this approach, an assay was developed (RenDx Fungi-
plex) for diagnosing IA using a generic Aspergillus probe, and for
diagnosing IC by combining a broad-range Saccharomycetales
yeast probe with a probe specific for pathogenic species belonging
to the diploid arm of the Candida clade (C. albicans, C. dublinien-
sis, C. parapsilosis, and C. tropicalis) (15). The assay has the added
benefit of differentiating potentially antifungal-resistant species
(Candida glabrata, Candida krusei, and Aspergillus terreus)
through specific probes. This paper describes the process of ana-
lytical and clinical evaluations of the assay when testing multiple
sample types, as well as nucleic acid (NA) extraction methods in
keeping with EAPCRI recommendations.
MATERIALS AND METHODS
Analytical performance. A summary of the process used to determine
analytical performance is shown in Fig. 1.
Determining the limit of detection of PCR-SERS. To evaluate the
limit of detection (LOD) of PCR amplification combined with SERS de-
tection, 40 replicates of two concentrations (200 and 20 copies per PCR)
and nine replicates of two lower concentrations (2 and 1 copy per PCR) of
quantified plasmids containing the 18S or 28S rRNA PCR target, for a
range of Candida and Aspergillus species, respectively, were tested. To
determine assay robustness, PCR amplification of the two higher concen-
trations (200 and 20 copies per reaction) was performed on five separate
occasions using four different types of PCR instruments (Bio-RadMyCycler
X2, Bio-Rad T100, Applied Biosystems Veriti, and GRI G-Storm); repli-
cate testing was split equally (n 8) across the platforms (Table 1). At the
lower concentrations (2 and 1 copy per reaction), amplification was per-
formed on the Bio-Rad MyCycler only.
Determining the limit of detection of the entire molecular process
(extraction–PCR-SERS detection). To investigate the influence of NA
extraction on the LOD, various simulated sample types (EDTA whole
blood [WB], serum, and plasma) containing clinically relevant concen-
trations (100 to 10 genome equivalents per ml of sample) of the pertinent
fungal pathogens were prepared. A total of 93 simulated samples were
tested (Table 2). The WB samples were spiked with quantified fungal
organism (Aspergillus conidia or Candida blastospore), whereas genomic
DNAwas used for the serum/plasma samples.NAwas extracted according
to EAPCRI recommendations (5, 6). Three-milliliter samples ofWBwere
extracted using red and white blood cell lysis, followed by mechanical
disruption of the fungal cells by bead beating and automated NA purifi-
cation/precipitation using the tissue kit on the Qiagen EZ1 Advanced XL
instrument (Qiagen, United Kingdom). For serum/plasma, NA was ex-
tracted from 0.5-ml volumes using the Qiagen EZ1 DSP virus kit on the
same platform. All NA was eluted in 50 to 60 l. PCR amplification was
performed using the Applied BiosystemsVeriti instrument (Life Technol-
ogies, United Kingdom) (Fig. 2).
Determining the range of detection and cross-reactivity. To deter-
mine the analytical specificity (detection range/cross-reactivity), a panel
of genomic DNA extracted from large quantities (106 organisms) of the
following fungal genera/species was tested: Absidia spp., Cunninghamella
spp., Rhizopus spp., Fusarium oxysporum, Fusarium dimerum, Scedospo-
rium apiospermum, Scedosporium prolificans, Penicillium spp., Exophiala
spp., Epidermophyton floccosum, Trichophyton mentagrophytes, Tricho-
phyton tonsurans, Trichophyton rubrum,Microsporum spp.,Aspergillus fu-
migatus (n 5),A. terreus (n 4),A. flavus (n 4),Aspergillus niger (n
2), Aspergillus glaucus, Aspergillus versicolor, Aspergillus ustus, Aspergillus
candidus, C. albicans (n  5), C. krusei (n  5), C. glabrata (n  5), C.
tropicalis (n  5), C. parapsilosis (n  2), Candida lusitaniae, Candida
viswanathii,Candida kefyr, Saccharomyces cerevisiae,Bipolaris spp., Scopu-
lariopsis brevicaulis, Cladosporium spp., Acremonium spp., and Blastoschi-
zomyces capitatus.
PCR amplification and SERS detection. PCR-SERS testing was per-
formed, according to themanufacturer’s instructions, using 10l of DNA
template in a final reaction volume of 50 l, targeting the 18S rRNA and
28S rRNA genes, and generating an amplicon ranging from 200 to 500 bp,
dependent on species. A no-template control (NTC) was included in ev-
ery PCR run and, for experiments testing simulated samples, quantified
plasmids containing the PCR target were included in order to assess PCR
efficiency. Tomonitor for sample inhibition, a quantified amount of plas-
mid containing a potato gene was added, and a control PCR was per-
formed. Given the low concentrations of fungal DNA in blood samples,
the inhibition PCR was performed as a separate reaction to prevent com-
petition for reagents that might occur if both the fungal and control PCR
were performed in a single tube. In doing so, any potential reduction in
the sensitivity of the Fungiplex assay was avoided. All testing was per-
formed with the user blinded to the original identity of the sample. An
overview of the process is shown in Fig. 2. The total process, including
extraction, was completed within one working day (8 h), with the PCR
amplification-SERS analysis taking approximately 6 h to complete, and a
hands-on time of approximately 1 to 2 h, including extraction, was
needed. The results (positive, negative, or inhibitory) were interpreted
automatically by the instrument, using a direct classical least-squares
model of analysis, which requires no manual spectroscopic expertise.
Determination of clinical performance. Fungal PCR is offered as a
routine diagnostic test for patients at high risk of developing IFD (1, 17).
On completion of the tests, NA extracts and surplus serum/plasma sam-
ples are retained for internal quality control and performance assessment
purposes. A total of 195 NA extracts from 112 patients were tested by the
Fungiplex assay. The patients were a combination of hematology patients
(n 83), abdominal surgery patients (n 27), a renal transplant patient,
and one patient suffering from chronic granulomatous disease. Forty-
four hematology patients received allogeneic stem cell transplantation.
The basic patient demographics are shown in Table 3. IFD was defined
according to the revised EORTC/MSG criteria, with PCR not used in
determining a diagnosis (3). Twenty-eight samples were from 14 patients
diagnosed with proven/probable IA, and nine samples were from three
cases of possible IA. Twenty-eight samples were from 15 patients with a
proven IC diagnosis. One hundred thirty samples were from 80 patients
having no evidence of fungal disease (NEF). The study was conducted as a
retrospective anonymous case-control study to assess the performance of
the Fungiplex assay, with no impact on patient management.
The NA extracts from patients previously tested by fungal PCR were
tested by the Fungiplex assay with the user blinded to the previous PCR
result and to the diagnosis of IFD (17). NA was extracted from 0.5 ml
plasma/serum using the Qiagen EZ1 DSP virus kit, or from 3 ml of WB
according to EAPCRI recommendations combined with the Qiagen EZ1
tissue kit, with NA eluted in 50- to 60-l volumes (5, 6). For all extrac-
tions, positive and negative extraction controls were incorporated at the
time of extraction to monitor assay performance. On completion of the
routine testing, the extracts were stored at 80°C before being tested by
the Fungiplex assay. PCR testing was performed on these extracts as de-
scribed above using the Applied Biosystems Veriti instrument, and an
inhibition control was used for every sample. For every run-quantified
plasmid, NTCs and simulated samples were included to assess PCR per-
formance. On completion of the testing, the results were independently
compared against the original diagnosis to determine assay performance.
Statistical analysis. To determine the validity of the Fungiplex assay
results, the positivity rate of samples originating from cases was compared
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to the false-positivity rate of the control samples. To determine the clinical
performance (sensitivity, specificity, positive and negative likelihood ra-
tios, and diagnostic odds ratio) of the Fungiplex assay, 2 by 2 tables were
constructed, using both proven/probable IFD and proven/probable/pos-
sible IFD as true cases and NEF patients as the control population. For all
patients, including those with multiple samples tested, only a single pos-
itive was required to consider the patient positive. Given the case-control
study design and the artificially high prevalence of IFD (28.6%), predic-
tive values were not used. Ninety-five percent confidence intervals were
generated for each proportionate value and, where required, P values
(Fisher’s exact test; P  0.05) were used to determine the significance of
the difference between the rates (18). The agreement between the Fungi-
plex assay and the original real-time PCR results was determined by cal-
culating the kappa statistic and observed agreement (17, 19).
RESULTS
Limit of detection of PCR amplification and SERS detection.
The LODof the PCR-SERS process was determined by identifying
the lowest plasmid concentration that achieved a 95% repro-
ducibility of detection, and this is summarized in Table 1. When
testing a plasmid input of 200 copies per PCR, 11 of the 12 plas-
FIG 1 Overview of the analytical process.
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mids (eight Candida and four Aspergillus targets) achieved 100%
reproducibility, with one target (C. parapsilosis) achieving 97.5%
reproducibility. At the lower concentration of 20 input copies per
reaction, six targets achieved the prerequisite 95% reproducibility
limit, with four targets (C. glabrata,C. guilliermondii,C. lusitaniae,
andC. tropicalis) achieving90% reproducibility, and two targets
(C. krusei and A. niger) achieving 80% and 82.5% reproducibility,
respectively. The overall reproducibility for all targets at this input
was 92.1% (95% confidence interval [CI], 89.3 to 94.2%). The 38
false-negative results were distributed evenly between the dif-
ferent PCR platforms used (Bio-Rad MyCycler, 10; Bio-Rad
T100, 6; GRI G-Storm, 13; ABI Veriti, 9). At an input of two
plasmid copies per reaction, reproducibility ranged from 1/9
(11.1%; 95%CI, 2.0 to 43.5%) for A. fumigatus andC. lusitaniae,
to 5/9 (55.6%; 95% CI, 26.7 to 81.1%) for A. niger and C. guillier-
mondii, with an overall reproducibility of 37.0% (95% CI, 27.3 to
47.9%). At one input copy per reaction, the reproducibility was
11.1% for all targets.
Reproducibility of detection of the entiremolecular process.
The reproducibility of detection of the entire molecular process
(NA extraction–PCR amplification-SERS detection) was deter-
mined by testing 93 simulated samples and is summarized in Ta-
ble 2. At moderate (50 to 100 genomic equivalents [GE] per sam-
ple) and low (10 to 20 GE per sample) fungal burdens, the overall
reproducibility of detection rates were 97.1% (95% CI, 85.1 to
99.5%) and 89.8% (95% CI, 79.5 to 95.3%), respectively, with no
significant difference in performance between the different sam-
TABLE 1 Reproducibility of detection of the PCR-SERS process when testing quantified plasmid containing the PCR target
Target
Data for indicated total input copies per PCR
200 (n 40) 20 2 (n 9) 1
No. % (95% CI) No. % (95% CI) No. % (95% CI) No. % (95% CI)
C. albicans 40 100 (91.2–100) 38a 95.0 (83.5–98.6) 3 33.3 (12.1–64.6) 1 11.1 (2.0–43.5)
C. glabrata 40 100 (91.2–100) 37b 92.5 (80.1–97.4)
C. krusei 40 100 (91.2–100) 32c 80.0 (65.2–89.5)
C. guilliermondii 40 100 (91.2–100) 36d 90.0 (77.0–96.0) 5 55.6 (26.7–81.1) 1 11.1 (2.0–43.5)
C. parapsilosis 39e 97.5 (87.1–99.6) 38f 95.0 (83.5–98.6) 4 44.4 (18.9–73.3) 1 11.1 (2.0–43.5)
C. lusitaniae 40 100 (91.2–100) 36g 90.0 (77.0–96.0) 1 11.1 (2.0–43.5) 1 11.1 (2.0–43.5)
C. tropicalis 40 100 (91.2–100) 37h 92.5 (80.1–97.4) 4 44.4 (18.9–73.3) 1 11.1 (2.0–43.5)
C. dubliniensis 40 100 (91.2–100) 39i 97.5 (87.1–99.6) 4 44.4 (18.9–73.3) 1 11.1 (2.0–43.5)
A. fumigatusj 40 100 (91.2–100) 38k 95.0 (83.5–98.6) 1 11.1 (2.0–43.5) 1 11.1 (2.0–43.5)
A. terreus 40 100 (91.2–100) 39l 97.5 (87.1–99.6)
A. niger 40 100 (91.2–100) 33m 82.5 (68.1–91.3) 5 55.6 (26.7–81.1) 1 11.1 (2.0–43.5)
A. flavus 40 100 (91.2–100) 39n 97.5 (87.1–99.6) 3 33.3 (12.1–64.6) 1 11.1 (2.0–43.5)
Overall 479/480 99.8 (98.8–100) 442/480 92.1 (89.3–94.2) 30/81 37.0 (27.3–47.9) 9/81 11.1 (6.0–19.8)
a One replicate missed using the Bio-Rad MyCycler, and one replicate missed using the GRI G-Storm.
b One replicate missed using the Bio-Rad MyCycler, and two replicates missed using the GRI G-Storm.
c One replicate missed using the Bio-Rad MyCycler, two replicates missed using the Bio-Rad T100, and five replicates missed using the GRI G-Storm.
d One replicate missed using the Bio-Rad MyCycler, and three replicates missed using the GRI G-Storm.
e One replicate missed using the Applied Biosystems Veriti.
f One replicate missed using the Bio-Rad MyCycler, and one replicate missed using the Bio-Rad T100.
g One replicate missed using the Bio-Rad MyCycler, two replicates missed using the Bio-Rad T100, and one replicate missed using the Applied Biosystems Veriti.
h Two replicates missed using the Bio-Rad MyCycler, and one replicate missed using the Applied Biosystems Veriti.
i One replicate missed using the Bio-Rad T100.
j For comparative purposes, the mean number of copies of the rRNA genes per genome of A. fumigatus is 54 (16). Consequently, 200 copies per reaction equates to approximately 4
genomes, whereas 20, 2, and 1 copy equates to1 genome per reaction. One A. fumigatus conidium contains one genome.
k Two replicates missed using the Applied Biosystems Veriti.
l One replicate missed using the GRI G-Storm.
m One replicate missed using the Bio-Rad MyCycler, one replicate missed using the GRI G-Storm, and five replicates replicate missed using the Applied Biosystems Veriti.
n One replicate missed using the Bio-Rad MyCycler.
TABLE 2 Reproducibility of detection of the entire molecular process
(nucleic acid extraction, PCR amplification, and SERS detection) by
testing simulated samples with various concentrations of fungal burden
Target
Load (GE) by sample type at the indicated copy no.
Serum/plasma
EDTA whole
blood Combined
50–100 10–20 50–100 10–20 50–100 10–20
C. albicans 4/4 4/4 1/1 2/2 5/5 6/6
C. glabrata 4/4 2/4 1/1 2/2 5/5 4/6
C. krusei 3/4 3/4 1/1 2/2 4/5 5/6
C. guilliermondii 2/2 3/3 2/2 3/3
C. parapsilosis 4/4 3/3 4/4 3/3
C. lusitaniae 4/4 3/3 4/4 3/3
C. tropicalis 2/2 2/2 2/2 2/2
C. dubliniensis 2/2 2/2 2/2 2/2
A. fumigatusa 1/1 8/9 4/4 4/4 5/5 12/13
A. terreus 2/3 2/2 4/5
A. niger 3/3 1/2 4/5
A. flavus 3/3 2/2 5/5
Overall 26/27 38/43 7/7 15/16 33/34 53/59
a For comparative purposes, the mean number of copies of the rRNA genes per genome
of A. fumigatus is 54 (16). Consequently, 10 genomes per sample equates to 540 copies
per sample. When testing a sample with a 10 GE or conidial burden and assuming
100% extraction efficiency, combined with an elution volume of 60 l and a PCR
template input volume of 10 l, the total input equals 90 copies or 1.6 GE/conidia per
reaction. One A. fumigatus conidium contains one genome.
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ple types at either burden level (moderate burden, P  1.0; low
burden, P 0.2199).
Analytical specificity: detection range and cross-reactivity.
In testing the robustness of the detection range, a total of 44
strains, comprising eight species of both Candida and Aspergillus,
were tested. Five strains of both C. krusei and C. glabrata were
correctly identified by their specific probes. All other species of
Candida were detected by one or both of the generic probes. Four
FIG 2 Overviewof theFungiplexassayprocess.DNAis extracted fromtheclinical sampleaccording toEAPCRIrecommendations.PCRisperformedusingbiotinylated
oligonucleotides, after which the PCR products are subsequently denatured. Specific and optimized multiplex SERS probes are then added and, if DNA from a target
organism is present, the appropriate probe is hybridized to the biotinylated PCR product. The samples are then transferred to the RenDx SP-1000 for automated
processing. LabeledDNAis capturedonto streptavidin-coatedmagnetic beads (via thebiotin label),which are then immobilized, allowing the excess and residual probes
tobe removedbywashing.Theamplicon-probecomplexes are thenelutedand transferred toa clean96-well detectionplate,while themagneticbeads andattachedDNA
are discarded. At the final stage, the SERS detection reagents (silver colloidal suspension) are added and the plate is transferred to the SA-1000 for Raman spectroscopic
analysis. Themanual steps are in theboxeswithdashed lines. Thenucleic acid extraction step canbe automated; this is dependent on themethodused and sample tested.
For whole-blood samples, when performed according to EAPCRI recommendations, the process is semiautomated (5).
TABLE 3 Patient demographics with EORTC/MSG diagnosis of aspergillosis
Demographic
Data by fungal infection type (n)a
Proven/probable IA (14) Possible IA (3) IC (15) No IFD (80)
Male/female ratio 0.75/1 2/1 1.1/1 1.1/1
Mean age (range) (yr) 53.8 (25–72) 69.3 (66–73) 58.8 (27–82) 53.1 (20–84)
Underlying condition (n) AML/MDS (5), ALL (2), AA (2),
lymphoma (2), CML/CLL (2),
renal transplant (1)
AML/MDS (3) Abdominal surgery (15) AML/MDS (43), abdominal surgery
(12), ALL (10), lymphoma (6),
AA (2), CML/CLL (2), CGD (1),
Other (4)
HSCTb Allo (5) Allo (0) NA Allo (39), auto (1)
Fungal disease
manifestation
IPA (9), IPA/sinusitis (1), sinusitis
(2), IPA/aspergilloma (1),
ABPA (1)
IPA (3) Candidemia (7), peritonitis (6),
abdominal abscess (2)
None
No. of extracts tested 28 plasma 9 plasma 15 serum, 13 whole blood 96 plasma, 34 serum
a IA, invasive aspergillosis; IC, invasive candidiasis; IFD, invasive fungal disease; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic
leukemia; lymphoma, Hodgkin, non-Hodgkin lymphoma, lymphoprofilerative disorder, and diffuse large B cell lymphoma; AA, aplastic anemia; CML, chronic myeloid leukemia;
CLL, chronic lymphoblastic leukemia; Other, other nonspecified hematological malignancy; CGD, chronic granulomatous disease; allo, allogeneic; NA, not applicable; auto,
autologous; IPA, invasive pulmonary aspergillosis; ABPA, allergic bronchopulmonary aspergillosis.
b HSCT, hematopoietic stem cell transplantation.
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strains of A. terreuswere correctly identified by the specific probe,
and six of the seven remainingAspergillus species were detected by
the generic probe.A. ustus, despite being successfully amplified by
PCR, did not generate a positive SERS signal, and the sequencing
of the amplicon showed only 83.3% similarity with the generic
Aspergillus probe.
Potential cross-reactivitywas noted for one of the 23 additional
fungal species tested, with F. oxysporum cross-reacting with both
the Saccharomycetales probe and the probe specific for pathogenic
Candida (C. albicans, C. dubliniensis, C. parapsilosis, and C. tropi-
calis). A sequence alignment of the oligonucleotides showed
90.9% and 86.4% similarities with the forward and reverse Can-
dida primers, respectively, and 100% and 80.8% similarities with
the Saccharomycetales and generic Candida probes, respectively.
Repeat testing of the original DNA confirmed this finding. How-
ever, the sequencing of both amplicons provided an identification
of C. parapsilosis, suggesting sampling error or contamination
with C. parapsilosis DNA. This cross-reactivity was not seen with
other Fusarium species tested. S. cerevisiaewas also detected by the
Saccharomycetales probe but was not considered cross-reactivity,
as it is part of this order. An additional sequence alignment
showed that potential cross-reactivity between Penicillium species
and the Aspergillus assay and Trichosporon species and the generic
Candida assay might occur. Upon testing Penicillium species, in-
termittent false positivitywas noted, and further investigations are
ongoing.
Clinical performance: sample positivity rates.Of the 28 sam-
ples originating from patients with IC, 18 generated a positive
Candida SERS signal (positivity rate, 64.3%; 95% CI, 45.8 to
79.3%). For patients with proven/probable IA, the sample positiv-
ity rate was 20/28 (71.4%; 95%CI, 52.9 to 84.8%) compared to 2/9
(22.2%; 95% CI, 6.3 to 54.7%) for patients with possible IA. The
overall positivity rate for the samples originating from cases of
proven/probable IFD was 38/56 (69.7%; 95% CI, 54.8 to 78.6%),
and for proven/probable/possible IFD, it was 40/65 (61.5%; 95%
CI, 49.4 to 72.4%).
When testing serum, plasma, and WB samples, the positivity
rates were 8/15 (53.3%; 95% CI, 30.1 to 75.2%), 20/28 (71.4%;
95% CI, 52.9 to 84.8%), and 10/13 (76.9%; 95% CI, 49.8 to
91.8%), respectively, for samples originating from cases of prov-
en/probable IFD.
The false-positivity rate (i.e., a positive signal in the samples
fromNEF patients) was 12/130 (9.2%; 95% CI, 5.4 to 15.4%) and
was significantly lower than the true positivity rates (Candida dif-
ference, 55.1%; 95% CI, 35.6 to 70.6%, P  0.0001; Aspergillus
difference, 62.2%; 95% CI, 42.7 to 76.1%; P  0.0001; overall
difference, 58.6%; 95% CI, 44.2 to 70.0%; P 0.0001), showing a
significant association between assay positivity and proven/prob-
able IFD (P 0.0001). False positivity was significantly greater in
serum (9/34 [26.5%]) than in plasma (3/96 [3.1%]) (difference,
23.4%; 95% CI, 10.2 to 40.1%; P  0.0022) samples. No WB
samples from NEF patients were tested. False positivity was split
equally between Candida (n  6) and Aspergillus (n  5) organ-
isms, with one sample generating a positive signal for both targets.
Clinical performance: concordancebetweenPCRassays.The
overall observed agreement between the original real-time PCR
result and the retest RenDx result was 80.5% (95% CI, 73.4 to
87.6%), generating a kappa statistic of 0.552, representing mod-
erate agreement between the assays (Table 4). The kappa statistics
specifically for Candida and Aspergillus detection were 0.416
(moderate agreement) and 0.596 (good agreement), respectively.
The kappa values specifically for serum and plasma testing were
0.315 (fair agreement) and 0.605 (good agreement), respectively
(results not shown). The observed agreement was significantly
greater when confirming the results for the samples originating
from patients without IFD (117/130 [90.0%]) compared to the
results for the samples originating from patients with IFD (40/65
[61.5%]) (difference, 28.5%; 95% CI, 15.9 to 41.3%, P 0.0001).
Consequently, 115/124 (92.7%) originally negative real-time PCR
results were also negative by the Fungiplex assay, and 42/71
(59.2%) of the originally positive real-time PCR results were con-
firmed by the Fungiplex assay (difference, 33.5%; 95% CI, 21.4 to
45.7%; P 0.0001).
Clinical performance parameters. The performance of the
RenDx Fungiplex assay is summarized in Table 5. The sensitivity
was similar for detecting both Aspergillus (85.7%) and Candida
(80.0%). The specificity was 87.5% and was improved (97.5%;
95% CI, 87.7 to 99.7%) by using a more stringent positivity
threshold (2 samples required to be RenDx Fungiplex positive),
albeit at the expense of sensitivity (31.0%; 95%CI, 13.5 to 55.8%).
The sensitivity varied with IC disease manifestation and was
higher for cases of candidemia (100%; 95%CI, 64.6 to 100%) than
for those from other IC infections, such as peritonitis or abdom-
inal abscesses (62.5%; 95%CI, 30.6 to 86.3%), although the num-
bers were limited. Sensitivity also varied with sample type and was
lowest when testing NA extracted from serum (53.3%; 95% CI,
30.1 to 75.2%), followed by WB (76.9%; 95% CI, 49.7 to 91.8%)
and plasma (85.7%; 95% CI, 60.1 to 96.0%).
DISCUSSION
A preliminary clinical evaluation of the RenDx Fungiplex assay
shows promising clinical performance, and it is coupled with the
benefits of commercial manufacture to ISO13485, requiring a
comprehensive quality management system for the design and
manufacture of medical devices. The overall sensitivity of 82.8%
(95% CI, 58.1 to 94.8%) for detecting cases of both IC and IA was
not unduly influenced by the performance of either arm of the
assay. The sensitivity for detecting cases of IA (85.7; 95% CI, 48.7
to 98.2%) was comparable to the sensitivities generated by meta-
analyses evaluating the performance of Aspergillus PCR assays for
testing both blood (88%) and bronchoalveolar lavage (BAL) fluid
(79%) samples (20, 21). The sensitivity for detecting cases of IC
was 80.0% (95%CI, 44.6 to 96.0%) butwas 100% (95%CI, 64.6 to
100%) for detecting cases of candidemia, similar to the results
TABLE 4 Comparison of Fungiplex and original real-time PCR results
Sample subset (total n 195)a
No. with real-time
positive result
No. with real-time
negative result
Fungiplex positive 42 9
Fungiplex negative 29 115
Samples from patients at risk of IA
(n 133)
Fungiplex positive 23 2
Fungiplex negative 18 90
Samples from patients at risk of IC
(n 62)
Fungiplex positive 19 7
Fungiplex negative 11 25
a IA: invasive aspergillosis; IC, invasive candidiasis.
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generated in a meta-analysis of Candida PCR, in which the sensi-
tivity fell from 95 to 100% for candidemia to 73% for proven/
probable/possible IC (22). When localized disease is suspected
and the patient is not fungemic, testing samples specific to the
particular site may be beneficial, as biomarker availability in the
circulation may be limited.
The specificity was 87.5% (95%CI, 74.7 to 94.5%), comparing
favorably with the specificities determined in the various meta-
analyses (range, 75% to 94%) (20–22). False positivity was associ-
ated equally with the two pathogens (Candida, n 6; Aspergillus,
n 5) butmorewith serum testing (P 0.0022).However, serum
testing was associated with post-abdominal surgery patients, and
it may be the patient population rather than the sample type caus-
ing this false positivity. Biomarker false positivity has been noted
in this population, hypothetically associated with translocation of
flora from the gastrointestinal (GI) tract. In the study by León et
al. (23), combining two biomarker assays improved sensitivity but
reduced specificity compared to that for (1,3)--D-glucan testing.
In half of the false-positive cases generated by the Fungiplex assay,
other biomarker assays were positive, perhaps representing undi-
agnosed disease. Specificity was increased by using a multiple-
positive threshold (2 samples positive), with only two cases gen-
erating two false-positive results, although this significantly
compromises sensitivity (Table 5).
The sensitivity as determined by retrospective analysis is likely
too low for the assay to be used as a screening test. However, the
Fungiplex assay performance may be further enhanced by a pro-
spective evaluation. In the initial retrospective case-control study
of theMycAssay Aspergillus assay, the sensitivity for testing serum
samples was 60 to 70% but increased to 100% on prospective
testing (9, 10). The potential improvement in sensitivity through
prospective evaluationmaybe sufficient for the Fungiplex assay to
be used as a screening assay to exclude IFD. Long-term storage of
samples and the effect of freeze-thawing may result in the degra-
dation of DNA. If DNAwas already at a concentration close to the
limit of reproducible real-time PCR detection when originally
tested, degradation might result in false negativity on retesting.
This might also explain why the concordance between the initial
positive PCR results from the cases was lower than that for the
negative PCR results from the controls. Unfortunately, the limited
original NA eluate and availability of stored samples prevented
further retesting. Consequently, in this study, it is not possible to
determine if SERS detection provides superior sensitivity over
real-time technology, as proposed elsewhere (14). Being a case-
control study, it is not designed to determine the clinical utility of
the Fungiplex assay, and a prospective cohort study is required to
provide accurate clinical validity and utility.
A major strength of the evaluation is that it is in accordance
with the EAPCRI recommendations for the extraction of fungal
DNA from whole blood and serum, allowing a standardized ap-
proach for both sample processing and, through commercial
manufacture of the Fungiplex assay, PCRdetection. The commer-
cial kits are quality controlled, and the methodology is standard-
ized in line with other commercial fungal biomarker tests (galac-
tomannan [GM] enzyme-linked immunosorbent assay [ELISA]
and [1,3]--D-glucan). Analytical performance should therefore
be robust across study centers, providing identical performance
without local optimization and expertise required to develop an
in-house test. Several commercial assays are available, although
most target either an individual fungal pathogen (MycAssay
Aspergillus and T2MR Candida) or, despite targeting both Can-
dida and Aspergillus, have received validation for one pathogen
only (Roche SeptiFast) (8–12). The Fungiplex assay has received
validation for both targets and has the added benefit of being an
open platform with broad multiplexing capacity (currently up to
10 targets), allowing the user to develop bespoke assays targeting
other fungal pathogens, as directed by local epidemiology.
In conclusion, this is the first evaluation of the novel, commer-
cially manufactured, and quality controlled RenDx Fungiplex as-
say. Initial evidence suggests that the assay provides promising
clinical performance, although further clinical validity and utility
need to be determined through a prospective evaluation. By pro-
viding a commercial PCR option, in combination with EAPCRI
recommendations, PCR testing for IFD can be standardized.
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TABLE 5 Clinical performance of the RenDx Fungiplex assay
Parametera
Data by Fungiplex comparisonb
Proven/probable IFD
vs NEF (n 109)
Proven/probable/possible
IFD vs NEF (n 112)
Proven/probable IA vs
NEF and IC (n 109)
IC vs NEF and proven/
probable IA (n 109)
Sensitivity (no. detected/total
no., % [95% CI])
24/29, 82.8 (58.1–94.8) 26/32, 81.3 (57.9–93.6) 12/14, 85.7 (48.7–98.2) 12/15, 80.0 (44.6–96.0)
Specificity (no. detected/total
no., % [95% CI])
70/80, 87.5 (74.7–94.5) 70/80, 87.5 (74.7–94.5) 83/95, 87.4 (74.7–94.5)c 84/94, 89.4 (74.7–94.5)
LR positive 6.62 6.50 6.86 6.4
LR negative 0.20 0.21 0.16 0.23
DOR 33.60 30.33 42.00 28.00
a CI, confidence interval; LR, likelihood ratio; DOR, diagnostic odds ratio.
b IFD, invasive fungal disease; NEF, no evidence of fungal disease; IA, invasive aspergillosis; IC, invasive candidiasis.
c Two patients diagnosed with IC were positive for both Candida and Aspergillus by the Fungiplex assay. These were considered false positives with regard to the Aspergillus result.
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